Dr. Robert Gundel joins Amorfix as Vice President, Research & Development
Amorfix Life Sciences announced that Robert Gundel, Ph.D., M.B.A., has been appointed the company's Vice President, Research & Development.
Dr. Gundel has 25 years of drug development experience with both major pharmaceutical and smaller biotechnology companies focusing on therapeutic monoclonal antibodies and vaccines. Before joining Amorfix, Dr. Gundel was the Chief Scientific Officer at Heat Biologics, a clinical stage company developing novel vaccine and monoclonal antibody technologies for the treatment of autoimmune diseases and cancers. Prior to Heat Biologics, Dr. Gundel was the Vice President and Head of Research at Elusys Therapeutics Inc. where he directed all research and development programs in the areas of vaccines, anti-infectives and the anti-anthrax toxin monoclonal antibody, Anthem(TM), being developed in collaboration with the National Institute of Allergy and Infectious Diseases and the Department of Homeland Security for stockpiling as part of the U.S. biodefense program against potential terrorist attacks. Prior to that, Dr. Gundel was the Chief Scientific Officer at Arius Research, Inc. which was recently purchased by Roche. Earlier in his career, Dr. Gundel served as Vice President, Pharmacology and Preclinical Research at Chiron Corporation, Director of Pharmacology at Bayer Corporation, and Vice President, Preclinical Research and Scientific Corporate Development at XOMA (US), LLC. He began his career in pharmaceutical R&D at Boehringer Ingelheim Pharmaceuticals, Inc.
Other news from the department people
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Elan and Transition Therapeutics Achieve Patient Enrollment Target in Phase 2 Clinical Study of ELND005 (AZD-103)
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement with GSK
GATC acquires SOLiD DNA Sequencer from Applied Biosystems
MorphoSys Grants ImmunoGen Access to HuCAL GOLD®
CryoLife reports record second quarter revenues
Lifespin partners with the Leipzig Research Center for Civilization Diseases to obtain deep clinical insights for obesity and diabetes
DFG Forschungszentrum für Molekularphysiologie des Gehirns (CMPB) - Göttingen, Germany
Nventa assembles group of international experts for its Clinical and Scientific Advisory Board
Microscopy: Overcoming the traditional resolution limit for the fast co-tracking of molecules - Researchers have developed an innovative method to simultaneously track rapid dynamic processes of multiple molecules at the molecular scale
New tests identify very early changes in Alzheimer's disease before symptoms appear
